Full-Time

Associate Director – Senior Counsel

Clinical

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA

Hybrid

Three days on-site per week required.

Bachelor's, JD

Category
Legal (1)
Required Skills
CAD
Google Cloud Platform

Get referred to CSL

See people who can refer or advise you

Requirements
  • Bachelor's Degree required
  • Juris Doctor required
  • Must be licensed to practice law in Pennsylvania or hold (or be eligible for and able to obtain promptly) a Limited In-House Corporate Counsel License under PA Business Law Edition Rule 302.
  • Minimum of 8 years practicing law, with 5 years of experience in a health care environment.
  • Strong familiarity with global clinical development laws and regulations (including GCP/ICH), and health care regulations (including fraud and abuse, anti-kickback, and FDA).
  • Strong drafting and negotiation skills are required, as well as ability to produce quality work under pressure and while balancing multiple priorities.
  • Strong communication, analytical, project management, problem solving, interpersonal, and teamwork skills are required.
Responsibilities
  • In support of the Clinical Development team, draft, review, and negotiate all agreements as directed by the Lead Counsel, Global Clinical Development, that are not otherwise managed by CRO, procurement, or clinical contracting teams.
  • This will include a range of bespoke agreements for which templates do not exist, for arrangements that are of key strategic importance for CDO and involve a high level of risk and complexity.
  • Agreement types include but are not limited to clinical trial research agreements, clinical vendor agreements, clinical manufacturing agreements, and clinical trial supply.
  • Collaborate with the R&D/Strategy transactional legal team to support all clinical development components of the agreements supported by that team, ensuring CDO’s requirements are incorporated, and any issues appropriately escalated.
  • Provide advice with respect to a broad range of legal and regulatory issues related to CSL’s global clinical development activities.
  • Provide strong business partnering support for CSL’s Global Clinical organization, ensuring clear communication, strong collaboration and proper information flow.
  • Undertake any research on a range of clinical related legal and regulatory issues, as required by the Lead Counsel, Global Clinical Development, or the business.
  • Stay apprised of and generate training content on clinical legal issues and emerging external trends as required by the Lead Counsel, Global Clinical Development and Global Lead, Clinical Contracting for delivery to the business and to the clinical contracting teams.
  • Act as the primary escalation and resolution point for any legal or contracting issues raised, and if necessary, escalate any unresolvable issues to the Lead Counsel, Global Clinical Development.
  • Draft, as assigned by Lead Counsel, Global Clinical Development, new templates required to support global clinical development. Review frequently negotiated agreement clauses, collaborate with the business to reassess the company’s risk appetite (as needed) and revise clauses accordingly.
  • As assigned, provide legal advice and support in connection with non-routine special projects for Global Clinical Development and for other matters or areas that business needs may dictate, or as otherwise required by the Lead Counsel, Global Clinical Development. This will require strong cross functional, global collaboration.
Desired Qualifications
  • Experience in an international environment, in-house or private practice, highly desirable.
  • Strong proficiency with Microsoft Office Suite (Word, Outlook, Teams, One Note, and Excel)

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL realized US$176 million FY26 cost savings, above target, improving margins.
  • September 10, 2026 Lancet data strengthens AUJEMFLU's case with older adults and regulators.
  • CSL's VarmX collaboration funds Phase 3 VMX-C001, expanding into urgent-surgery anticoagulation reversal.

What critics are saying

  • FY26 reported a US$2.6 billion loss after US$7.1 billion impairments and restructuring.
  • Pentagon's April 2026 flu mandate repeal cuts Seqirus demand from a major buyer.
  • CSL reported March 2026 temporary global HEMGENIX availability issues, risking treatment continuity and trust.

What makes CSL unique

  • CSL's FY26 portfolio spans plasma, gene therapy, and leading influenza vaccines.
  • HEMGENIX posted 25% FY26 growth, sustaining durable haemophilia B demand.
  • AUJEMFLU won MHRA and European Commission approval, plus Lancet superiority data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.